DEK and urinary bladder cancer: Since its discovery, DEK was also shown to be increased in acute myeloid leukemia types that do not harbor the DEK-NUP214 fusion protein [20–22] and to be frequently overexpressed in solid tumors including colon, breast, gastric adenocarcinoma, ovarian carcinomas, bladder cancer, retinoblastoma, lung, pancreatic, neuroendocrine prostate cancer, hepatocellular, skin cancer, head and neck cancer squamous cell carcinoma (HNSCC), and esophageal squamous cell carcinoma (ESCC; S5 Fig) [23–40].